7.51
前日終値:
$7.11
開ける:
$7.13
24時間の取引高:
5.62M
Relative Volume:
1.42
時価総額:
$1.17B
収益:
$419.75M
当期純損益:
$-15.10M
株価収益率:
-78.80
EPS:
-0.0953
ネットキャッシュフロー:
$63.10M
1週間 パフォーマンス:
+8.37%
1か月 パフォーマンス:
+38.31%
6か月 パフォーマンス:
-24.90%
1年 パフォーマンス:
-31.60%
Certara Inc Stock (CERT) Company Profile
名前
Certara Inc
セクター
電話
(415) 237-8272
住所
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, BTSG, HQY, TEM, TXG
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CERT
Certara Inc
|
7.51 | 1.17B | 419.75M | -15.10M | 63.10M | -0.0953 |
|
VEEV
Veeva Systems Inc
|
186.24 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
72.91 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
HQY
Healthequity Inc
|
94.64 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
|
TEM
Tempus Ai Inc
|
42.69 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
TXG
10 X Genomics Inc
|
46.27 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-06 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2026-02-27 | ダウングレード | Craig Hallum | Buy → Hold |
| 2026-01-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-21 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-11-13 | 開始されました | BMO Capital Markets | Market Perform |
| 2025-09-29 | 開始されました | Craig Hallum | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-05-08 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-02-27 | 開始されました | TD Cowen | Buy |
| 2024-09-27 | アップグレード | UBS | Neutral → Buy |
| 2024-04-10 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-04 | 開始されました | JMP Securities | Mkt Perform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | UBS | Neutral |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2023-08-22 | ダウングレード | Jefferies | Buy → Hold |
| 2023-08-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-04-12 | 開始されました | Stephens | Overweight |
| 2023-04-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-12-14 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-09-08 | 開始されました | Berenberg | Buy |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-07-01 | 開始されました | Piper Sandler | Overweight |
| 2022-01-11 | アップグレード | Jefferies | Hold → Buy |
| 2021-08-05 | 再開されました | Credit Suisse | Neutral |
| 2021-07-23 | 開始されました | Robert W. Baird | Outperform |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-01-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-01-05 | 開始されました | BofA Securities | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Neutral |
| 2021-01-05 | 開始されました | Jefferies | Hold |
| 2021-01-05 | 開始されました | William Blair | Outperform |
すべてを表示
Certara Inc (CERT) 最新ニュース
Certara, Inc. (CERT) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Certara, Inc. (CERT) Stock Forecasts - Yahoo! Finance Canada
Technical Reactions to CERT Trends in Macro Strategies - Stock Traders Daily
How Certara’s NVIDIA AI Partnership Could Reshape CERT’s Long-Term Drug Development Narrative - webull.com
Certara Inc. (CERT) Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesEarnings Sentiment Score - dars.gov.et
Certara Inc. (CERT) Slides 4.8% as Shares Test Key Support LevelsCollar Trade - dars.gov.et
Certara files Form 3 for interim CFO Mohammed Faiz initial beneficial ownership statement - Bitget
Certara (CERT) interim CFO discloses stock, RSU and PSU holdings - Stock Titan
Why Did CERT Stock Fall Today? - Stocktwits
Certara to report Q2 2026 financial results on August 4 - scanx.trade
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026 - The Manila Times
Certara sets Aug. 4 call to discuss second-quarter results - Stock Titan
BlackRock, Inc.'s Strategic Acquisition of Certara Inc. Shares - GuruFocus
Pomerantz investigates Certara investors over p... - Pluang
Dimensional Fund Advisors details Certara Inc (CERT) 3.9% ownership position - Stock Titan
What Certara (CERT)'s NVIDIA BioNeMo Partnership Means For Shareholders - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc.CERT - PR Newswire
BlackRock (CERT) discloses 18.0M shares; 11.6% ownership reported - Stock Titan
AI Chips TodayCertara-NVIDIA Partnership Revolutionizes AI in Drug Development - Yahoo Finance
Certara partners with Nvidia to integrate AI agents into drug development platform - Investing.com UK
Nvidia Powers AI Agent Strategies for Certara, Silo PharmaNVIDIA (NASDAQ:NVDA) - Benzinga
Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT) - Yahoo Finance
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit - The Manila Times
Certara Accelerates Drug Discovery and Development With NVIDIA BioNeMo Agent Toolkit - 富途牛牛
Certara, Silo Pharma advance AI strategies with Nvidia initiatives - scanx.trade
Price to earnings forward of Certara, Inc. – HAM:700 - TradingView
Enterprise value to revenue forward of Certara, Inc. – NASDAQ:CERT - TradingView
Price to sales forward of Certara, Inc. – HAM:700 - TradingView
Certara Inc (NASDAQ: CERT) Share Price, CERT Stock News, CERT Share Price & Updates - Kalkine
Is Certara (CERT) Quietly Recasting Its Small-Cap Identity Around Biosimulation Advisory Leadership? - Yahoo Finance
Does Certara (CERT) Joining the Russell 2000 Recast Its Biosimulation Investment Narrative? - simplywall.st
CERT Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 2.75%Share Dilution Risk - DonanımHaber
Trading the Move, Not the Narrative: (CERT) Edition - Stock Traders Daily
William Blair Maintains Certara(CERT.US) With Hold Rating - Moomoo
Should You Investigate Certara, Inc. (NASDAQ:CERT) At US$6.36? - Moomoo
Certara, Inc. (CERT) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Pomerantz investigates Certara after revenue drop and CFO exit - scanx.trade
Certara Inc. (CERT) Rallies 8.9% – Key Support and Resistance Levels in FocusDealer Positioning - dars.gov.et
Certara, Inc.(NasdaqGS: CERT) added to Russell 2000 Index - marketscreener.com
Certara, Inc.(NasdaqGS: CERT) dropped from Russell Midcap Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Certara, Inc. – NASDAQ:CERT - TradingView
Certara, Inc.(NasdaqGS: CERT) dropped from Russell 1000 Dynamic Index - marketscreener.com
Enterprise value to EBIT forward of Certara, Inc. – NASDAQ:CERT - TradingView
Certara, Inc.(NasdaqGS: CERT) dropped from Russell Midcap Index - marketscreener.com
Price to book forward of Certara, Inc. – NASDAQ:CERT - TradingView
Price to book forward of Certara, Inc. – BMV:CERT - TradingView
Price to earnings forward of Certara, Inc. – BMV:CERT - TradingView
[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Certara, Inc. Actuals & Estimates (NASDAQ:CERT) - TradingView
CERT Forecast — Price Target — Prediction for 2027 - TradingView
Certara Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterAnalyst Consensus Shift - dars.gov.et
Certara Inc (CERT) 財務データ
収益
当期純利益
現金流量
EPS
Certara Inc (CERT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Corcoran Daniel | SVP and General Counsel |
Jun 01 '26 |
Option Exercise |
0.00 |
22,830 |
0 |
39,939 |
| Collins Cynthia | Director |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
51,846 |
| Reynders John V W | Chief Financial Officer |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
26,466 |
| BROSHY ERAN | Chairman |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
50,708 |
| Bedi Arjun | Director |
May 14 '26 |
Option Exercise |
0.00 |
5,547 |
0 |
5,547 |
| CASHMAN JAMES E III | Chairman |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
484,197 |
| Killefer Nancy | Director |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
51,846 |
| Crane Rosemary A | Director |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
45,672 |
| WALSH MATTHEW M | Director |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
213,316 |
| Resnick Jon Matthew | Chief Executive Officer |
May 11 '26 |
Option Exercise |
0.00 |
59,766 |
0 |
59,766 |
大文字化:
|
ボリューム (24 時間):